[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:small-lymphocytic-lymphoma:cd19-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Small Lymphocytic Lymphoma","CD19 Gene",7,[8,16,22,29,35,41,48],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06364423","Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:24.494016Z","2026-07-05T05:32:16.752213Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05702853","Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed\u002FRefractory NHL, CLL\u002FSLL",[12],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:28.285448Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT04892277","CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed\u002FRefractory B Cell Malignancies",[26],"Phase 1","2026-08-26T02:18:05.435729Z","2026-05-05T02:43:27.592999Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT03666000","Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed\u002FRefractory (r\u002Fr) Non-Hodgkin Lymphoma (NHL) and r\u002Fr B-cell Acute Lymphoblastic Leukemia (B-ALL)",[26],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:27.435593Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",[12],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.324190Z",{"nct_id":42,"title":43,"phases":44,"status":45,"updated_at":46,"content_modified":47},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[26],"ENROLLING_BY_INVITATION","2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z",{"nct_id":49,"title":50,"phases":51,"status":52,"updated_at":53,"content_modified":54},"NCT03331198","Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:36:24.364783Z","2026-05-05T02:43:29.139125Z"]